Angelucci, Emanuele
Mayo Clinic
Unità Operativa Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Citations 2
Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis
Perales, Miguel‐Angel , Awan, Farrukh T. , Patel, Jinalben , Castagna, Luca , Angelucci, Emanuele , Finel, Hervé , Kulagin, Alexander , Glass, Bertram , Herrera, Alex F. , Blaise, Didier , Kharfan‐Dabaja, Mohamed A. , Halahleh, Khalid , Jones, Richard J., Lynch, Ryan C. , Sauter, Craig S. , Ahn, Kwang Woo , Sureda, Anna , Boumendil, Ariane , Patel, Jinalben , Castagna, Luca , Angelucci, Emanuele , Finel, Herve , Corradini, Paolo , Herrera, Alex F , Blaise, Didier , Kharfan-Dabaja, Mohamed A , Halahleh, Khalid , Ahmed, Sairah , Martínez, Carmen , Giebel, Sebastian , Montoto, Silvia , Ahmed, Nausheen , de Lima, Marcos , Shadman, Mazyar , Ahn, Kwang W , Hamadani, Mehdi , Sureda, Anna , Perales, Miguel-Angel , Awan, Farrukh T , Boumendil, Ariane , Ahmed, Sairah , Montoto, Silvia , Ahmed, Nausheen , Lima, Marcos de , Shadman, Mazyar , Hamadani, Mehdi , Bazarbachi, Ali
Blood | July 7, 2025 | Volume: 146 | Issue: 8 | Pages: 1011-1029
Abstract Checkpoint inhibitors (CPIs) have shown remarkable efficacy in Hodgkin lymphoma (HL), and are now used routinely. While allogeneic hematopoietic cell transplantation (allo-HCT) remains a curative option for HL, there are concerns prior CPIs may exacerbate post–allo-HCT complications, particularly graft-versus-host disease (GVHD), and lead to worse outcomes. Given the relative paucity of data, we performed a Center for International Blood and Marrow Transplant Research/European Society for Blood and Marrow Transplantation study to examine the impact of prior CPIs in allo-HCT. We included 2186 adult patients aged >18 years who received a first allo-HCT using a matched related, unrelated, or haploidentical donor from 2008 to 2023. Twenty-seven percent of patients received prior CPIs. GVHD prophylaxis was posttransplant cyclophosphamide (PTCy) in 55.8% of patients in the CPI cohort, and 35% in the non-CPI cohort. Median follow-up among survivors was longer for the non-CPI (39 months) than CPI cohort (16.5 months). In multivariate analysis, prior CPI exposure did not affect overall survival (OS) or nonrelapse mortality, but resulted in improved progression-free survival (non-CPI vs CPI hazard ratio [HR], 0.81; 0.67-0.98; P = .03) and lower relapse incidence (HR, 0.58; 0.45-0.76; P < 001). While grade 2 to 4 (HR, 1.26; 1.04-1.53; P = .02) and 3 to 4 (HR, 1.41; 1.04-1.92; P = .03) acute GVHD (aGVHD) were increased, differences in chronic GVHD (cGVHD) were not significant. PTCy–based GVHD prophylaxis resulted in improved OS, lower grade 2 to 4 aGVHD, and cGVHD in patients with prior CPI exposure. In summary, allo-HCT should still be considered a curative option for patients with HL in the era of CPIs.
Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma
García, Héctor Alexander Velásquez , Spinelli, John J., Gaffney, Patrick M. , Smedby, Karin E. , Wang, Sophia , Adami, Hans‐Olov , Angelucci, Emanuele , Ansell, Stephen M. , Asmann, Yan W. , Becker, Nikolaus, Benavente, Yolanda , Berndt, Sonja I. , Bertrand, Kimberly A. , Birmann, Brenda M. , Boeing, Heiner , Bracci, Paige M. , Brennan, Paul , Brooks‐Wilson, Angela , Clavel, Jacqueline , Conde, Lucía , Cotenbader, Karen H, Cox, David G. , Crouch, Simon , Roos, Anneclaire J. De , Sanjosé, Sílvia de , Lollo, Simonetta Di, Diver, W. Ryan , Foretová, Lenka , Ghesquières, Hervé , Glimelius, Bengt , Haïoun, Corinne , Hartge, Patricia, Hjalgrim, Henrik , Holford, Theodore R. , Holly, Elizabeth A., Jackson, Rebecca D. , Kaaks, Rudolph, Kane, Eleanor , Klein, Robert J. , Kraft, Peter , Kricker, Anne , Lan, Qing , Lawrence, Charles , Liebow, Mark , Lightfoot, Tracy, Link, Brian K. , Maynadié, Marc, McKay, James , Melbye, Mads , Molina, Thierry Jo , Monnereau, Alain , Morton, Lindsay M. , Nieters, Alexandra, Novak, Anne J. , Offit, Kenneth , Purdue, Mark P. , Rais, Marco, Riby, Jacques, Roman, Eve , Rothman, Nathaniel , Salles, Gilles , Severi, Gianluca , Severson, Richard K., Skibola, Christine F., Smith, Martyn T. , Southey, Melissa C. , Staines, Anthony , Thompson, Carrie A. , Tilly, Hervé , Tinker, Lesley F. , Tjønneland, Anne , Turner, Jennifer , Vajdic, Claire M. , Vermeulen, Roel , Vijai, Joseph , Vineis, Paolo , Virtamo, Jarmo, Wang, Zhaoming , Weinstein, Stephanie J. , Zheng, Tongzhang, Zucca, Mariagrazia, Clarke, Ann E. , Smith, Alexandra , Bertrand, Kimberly A , Turner, Jennifer , Link, Brian K , Joseph, Vijai , Southey, Melissa C , Brooks-Wilson, Angela R , Vajdic, Claire M , Kane, Eleanor , Tjønneland, Anne , Wang, Zhaoming , Severi, Gianluca , Kraft, Peter , Morton, Lindsay M , De Roos, Anneclaire J , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Roman, Eve , Clavel, Jacqueline , Smith, Alexandra , Bernatsky, Sasha , Ramsey‐Goldman, Rosalind , Albanes, Demetrius , Boffetta, Paolo , Cerhan, James R. , Chanock, Stephen Jacob , Cozen, Wendy , Doǧan, Ahmet , Giles, Graham G. , Habermann, Thomas M. , Kelly, Rachel S. , North, Kari E. , Slager, Susan L. , Smith, Alex, Teras, Lauren R. , Witzig, Thomas E. , Zelenetz, Andrew D. , Zeleniuch‐Jacquotte, Anne , Zhang, Yawei , Angelucci, Emanuele , Klein, Robert
Lupus Science & Medicine | November 13, 2017 | Volume: 4 | Issue: 1 | Pages: e000187
Objective Determinants of the increased risk of diffuse large B-cell lymphoma (DLBCL) in SLE are unclear. Using data from a recent lymphoma genome-wide association study (GWAS), we assessed whether certain lupus-related single nucleotide polymorphisms (SNPs) were also associated with DLBCL. Methods GWAS data on European Caucasians from the International Lymphoma Epidemiology Consortium (InterLymph) provided a total of 3857 DLBCL cases and 7666 general-population controls. Data were pooled in a random-effects meta-analysis. Results Among the 28 SLE-related SNPs investigated, the two most convincingly associated with risk of DLBCL included the CD40 SLE risk allele rs4810485 on chromosome 20q13 (OR per risk allele=1.09, 95% CI 1.02 to 1.16, p=0.0134), and the HLA SLE risk allele rs1270942 on chromosome 6p21.33 (OR per risk allele=1.17, 95% CI 1.01 to 1.36, p=0.0362). Of additional possible interest were rs2205960 and rs12537284. The rs2205960 SNP, related to a cytokine of the tumour necrosis factor superfamily TNFSF4, was associated with an OR per risk allele of 1.07, 95% CI 1.00 to 1.16, p=0.0549. The OR for the rs12537284 (chromosome 7q32, IRF5 gene) risk allele was 1.08, 95% CI 0.99 to 1.18, p=0.0765. Conclusions These data suggest several plausible genetic links between DLBCL and SLE.